Private company

NPS Pharmaceuticals (United States)

NPS Pharmaceuticals (United States) is an American biological products company based in Bedminster.¹

Last updated Oct 20, 2026.

Overview

IndustryBiological Products, (No Diagnostic Substances)¹
HeadquartersBedminster¹
Websitewww.takeda.com
Incorporated inDE³
Business address550 Hills Drive, Bedminster, Nj 07921³
Filer categoryLarge accelerated filer³

See how the biggest companies compare on our leaderboards

What it owns

What NPS Pharmaceuticals (United States) reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Item	Latest	A year before	Change
Machinery and equipment	$223.0K⁴ Dec 31, 2014	$216.0K⁴ Dec 31, 2013	+3.2%
Furniture and fixtures	$8.3M⁴ Dec 31, 2014	$5.5M⁴ Dec 31, 2013	+51.2%
Leasehold improvements	$2.1M⁴ Dec 31, 2014	$2.0M⁴ Dec 31, 2013	+4.3%
Property and equipment, before depreciation	$10.7M⁴ Dec 31, 2014	$7.8M⁴ Dec 31, 2013	+37.6%
Accumulated depreciation	$4.9M⁴ Dec 31, 2014	$3.4M⁴ Dec 31, 2013	+45.8%
Property and equipment, net	$5.8M⁴ Dec 31, 2014	$4.4M⁴ Dec 31, 2013	+31.4%

Investments

Item	Latest	A year before	Change
Cash and cash equivalents	$65.6M⁴ Dec 31, 2014	$51.2M⁴ Dec 31, 2013	+28.0%
Marketable securities, current	$98.6M⁴ Dec 31, 2014	$129.3M⁴ Dec 31, 2013	−23.7%

Intangibles and goodwill

Item	Latest	A year before	Change
Goodwill	$9.4M⁴ Dec 31, 2014	$9.4M⁴ Dec 31, 2013	0%
Accumulated amortization	$601.0K⁴ Dec 31, 2014	$716.0K⁴ Dec 31, 2013	−16.1%
Finite-lived intangibles, net	$17.5M⁴ Dec 31, 2014	$19.3M⁴ Dec 31, 2013	−9.3%

Inventory

Item	Latest	A year before	Change
Inventory, total	$36.8M⁴ Dec 31, 2014	$30.0M⁴ Dec 31, 2013	+22.6%
Raw materials	$34.0M⁴ Dec 31, 2014	$29.3M⁴ Dec 31, 2013	+16.0%
Finished goods	$2.8M⁴ Dec 31, 2014	$705.0K⁴ Dec 31, 2013	+296.5%

Leadership

Who has led NPS Pharmaceuticals (United States), and when. Pick a name to see everywhere that person has worked.

Chief executive

Chair

Hunter Jackson2006

President

Chief financial officer

Chief operating officer

2010201520202025

Chief executive officerFrancois Nader Apr 17, 2008 to Feb 24, 2015⁵
Chief executive officerHunter Jackson Jan 19, 2006 to Apr 19, 2006⁶
ChairHunter Jackson Jan 19, 2006 to Apr 19, 2006⁶
PresidentPaul E. Firuta Feb 20, 2015 to Feb 24, 2015⁷
PresidentEric Pauwels May 7, 2014 to Feb 24, 2015⁸
PresidentFrancois Nader Apr 17, 2008 to Feb 24, 2015⁵
Chief financial officerLuke M. Beshar Nov 20, 2007 to Feb 24, 2015⁹
Chief financial officerGerard J. Michel Jan 19, 2006 to Oct 16, 2007¹⁰
Chief operating officerEric Pauwels Oct 19, 2011 to Oct 19, 2011¹¹
Chief operating officerFrancois Nader Jul 18, 2007 to Mar 19, 2008¹²

Board members and other officers (42)

SVP, Legal Affairs & GCChristine Mikail Cvijic Mar 7, 2014 to Feb 24, 2015¹³
SVP of Human ResourcesRobin D. Friedman Mar 13, 2014 to Feb 24, 2015¹⁴
Pres, US Commercial OperationsPaul E. Firuta Apr 4, 2014 to Apr 17, 2014¹⁵
VP of Corp Dev & StrategySusan E. Graf May 30, 2013 to Feb 24, 2015¹⁶
Chief Commercial OfficerEric Pauwels Sep 27, 2011 to Feb 14, 2014¹⁷
VP, Technical OperationsJoseph J. Rogus May 26, 2010 to Feb 24, 2015¹⁸
SVP, Commercial OperationsNancy Bryan May 26, 2010 to Feb 22, 2011¹⁹
VP, Reg. Affairs & Drug SafetyCottrell Sandra Apr 8, 2009 to Dec 21, 2012²⁰
SVP & Acting GCEd Stratemeier Oct 20, 2009 to Nov 10, 2011²¹
VP, Assist. GC & Sec.Andrew D. Rackear Jan 16, 2008 to Jul 16, 2008²²
SVP & CMORoger Garceau Dec 12, 2008 to Feb 24, 2015²³
SVP, Chief Commercial OfficerBrian O'Callaghan Oct 15, 2007 to Oct 16, 2007²⁴
VP, Regulatory AffairsDouglas N. Dobak Nov 1, 2007 to Oct 17, 2008²⁵
VP, Chief Medical OfficerAlan Mark Rauch Jan 19, 2006 to Apr 19, 2006²⁶
VP & Chief Scientific OfficerEdward F. Nemeth Jan 19, 2006 to Oct 18, 2006²⁷
VP, Marketing and SalesG. Thomas Heath Jan 19, 2006 to Apr 19, 2006²⁸
VP, Human ResourcesGlenn R. Melrose Jan 19, 2006 to Feb 18, 2014²⁹
Vice President, FinanceMorgan R. Brown Jan 19, 2006 to Oct 19, 2006³⁰
VP, ManufacturingStephen R. Parrish Jan 19, 2006 to Oct 18, 2006³¹
SVP, Regulatory AffairsGregory M. Torre Mar 6, 2006 to Jul 18, 2007³²
Senior VP Business DevelopmentJuergen Lasowski Apr 25, 2006 to Jul 18, 2007³³
Chief Medical & Commercial OffFrancois Nader Jun 7, 2006 to Jul 18, 2007³⁴
Senior VP, Legal AffairsVal R. Antczak Jun 15, 2006 to Oct 16, 2007³⁵
Board memberPierre Legault Nov 5, 2014 to Feb 24, 2015³⁶
Board memberGeorges Gemayel Mar 1, 2012 to Feb 24, 2015³⁷
Board memberPedro P. Granadillo Nov 19, 2010 to Feb 24, 2015³⁸
Board memberFrancois Nader Jan 20, 2009 to Feb 24, 2015³⁹
Board memberColin Broom Md. Jul 13, 2009 to Feb 24, 2015⁴⁰
Board memberCalvin Stiller Jan 19, 2006 to Apr 17, 2008⁴¹
Board memberDonald E. Kuhla Jan 19, 2006 to Feb 9, 2012⁴²
Board memberJames G. Groninger Jan 19, 2006 to Feb 24, 2015⁴³
Board memberJohn Robert Evans Jan 19, 2006 to Apr 21, 2006⁴⁴
Board memberJoseph Klein Iii. Jan 19, 2006 to May 24, 2007⁴⁵
Board memberMichael W. Bonney Jan 19, 2006 to Feb 24, 2015⁴⁶
Board memberPeter G. Tombros Jan 19, 2006 to Feb 24, 2015⁴⁷
Board memberRachel R. Selisker Jan 19, 2006 to Feb 24, 2015⁴⁸
Board memberSanto J. Costa Jan 19, 2006 to May 24, 2007⁴⁹
Board memberThomas N. Parks Jan 19, 2006 to Apr 21, 2006⁵⁰
Board memberHunter Jackson Jun 15, 2006 to May 24, 2007⁵¹
General counselEd Stratemeier May 7, 2010 to Feb 14, 2014⁵²
General counselAndrew D. Rackear Nov 16, 2007 to Jan 22, 2009⁵³
General counselVal R. Antczak Jan 19, 2006 to Jul 18, 2007⁵⁴

Timeline

Apr 17, 2008New chief executive Francois Nader becomes CEO⁵
Jan 19, 2006New chief executive Hunter Jackson becomes CEO⁶

SEC filer profile

How NPS Pharmaceuticals (United States) is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

Name on EDGARNPS PHARMACEUTICALS INC²
CIK0000890465
Employer ID (EIN)87-0439579²
Filer statusLarge accelerated filer²
Incorporated inDelaware²
Fiscal year endsDecember 31²
Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)²
Business address550 Hills Drive, Bedminster, NJ 07921²
Phone(908) 450-5300²
Shares outstanding108,581,155 as of Feb 11, 2015⁴
Public float$3.5T as of Jun 30, 2014⁴
On EDGAR sinceFeb 6, 1996²
Filings1,575 in all: 4 (826), 8-K (186), SC 13G/A (119), 10-Q (57), SC 13G (44), 3 (32), 425 (32), 4/A (31)²
All 55 form types
DEF 14A (19), 10-K (18), 10-K/A (13), 424B5 (13), S-3/A (13), UPLOAD (13), S-3 (12), S-8 POS (12), SC 13D/A (12), S-8 (11), CORRESP (10), ARS (9), CT ORDER (9), SC TO-C (8), 424B3 (7), SC 13D (7), EFFECT (6), POS AM (5), SC 14D9/A (5), SC TO-T/A (5), 10-Q/A (3), 8-K/A (3), 3/A (2), 424B7 (2), 8-A12G/A (2), DEFA14A (2), NT 10-Q (2), PRE 14A (2), REGDEX (2), S-3ASR (2), S-3MEF (2), SC TO-I/A (2), 10-C (1), 10-K405 (1), 15-12G (1), 25-NSE (1), 424B1 (1), 424B4 (1), 8-A12G (1), DEFM14A (1), FWP (1), POSASR (1), PREM14A (1), SC 14D9 (1), SC TO-I (1), SC TO-T (1), SC14D9C (1)
Latest filingsAnnual report (10-K) Feb 18, 2015
Quarterly report (10-Q) Nov 10, 2014
Proxy statement (DEF 14A) Apr 1, 2014
Latest 8-K (8-K) Feb 23, 2015

Sources

The numbers on this page point here. Each one links to the record it came from.

1
WikidataNPS Pharmaceuticals (United States) on Wikidata
2
SEC EDGARNPS Pharmaceuticals (United States) filings on SEC EDGAR
3
SEC EDGARNPS Pharmaceuticals (United States) filings on SEC EDGAR
4
SEC EDGARNPS Pharmaceuticals (United States) 10-K for fiscal 2014
5
SEC EDGARFrancois Nader, Chief executive officer
6
SEC EDGARHunter Jackson, Chief executive officer
7
SEC EDGARPaul E. Firuta, President
8
SEC EDGAREric Pauwels, President
9
SEC EDGARLuke M. Beshar, Chief financial officer
10
SEC EDGARGerard J. Michel, Chief financial officer
11
SEC EDGAREric Pauwels, Chief operating officer
12
SEC EDGARFrancois Nader, Chief operating officer
13
SEC EDGARChristine Mikail Cvijic, SVP, Legal Affairs & GC
14
SEC EDGARRobin D. Friedman, SVP of Human Resources
15
SEC EDGARPaul E. Firuta, Pres, US Commercial Operations
16
SEC EDGARSusan E. Graf, VP of Corp Dev & Strategy
17
SEC EDGAREric Pauwels, Chief Commercial Officer
18
SEC EDGARJoseph J. Rogus, VP, Technical Operations
19
SEC EDGARNancy Bryan, SVP, Commercial Operations
20
SEC EDGARCottrell Sandra, VP, Reg. Affairs & Drug Safety
21
SEC EDGAREd Stratemeier, SVP & Acting GC
22
SEC EDGARAndrew D. Rackear, VP, Assist. GC & Sec.
23
SEC EDGARRoger Garceau, SVP & CMO
24
SEC EDGARBrian O'Callaghan, SVP, Chief Commercial Officer
25
SEC EDGARDouglas N. Dobak, VP, Regulatory Affairs
26
SEC EDGARAlan Mark Rauch, VP, Chief Medical Officer
27
SEC EDGAREdward F. Nemeth, VP & Chief Scientific Officer
28
SEC EDGARG. Thomas Heath, VP, Marketing and Sales
29
SEC EDGARGlenn R. Melrose, VP, Human Resources
30
SEC EDGARMorgan R. Brown, Vice President, Finance
31
SEC EDGARStephen R. Parrish, VP, Manufacturing
32
SEC EDGARGregory M. Torre, SVP, Regulatory Affairs
33
SEC EDGARJuergen Lasowski, Senior VP Business Development
34
SEC EDGARFrancois Nader, Chief Medical & Commercial Off
35
SEC EDGARVal R. Antczak, Senior VP, Legal Affairs
36
SEC EDGARPierre Legault, Board member
37
SEC EDGARGeorges Gemayel, Board member
38
SEC EDGARPedro P. Granadillo, Board member
39
SEC EDGARFrancois Nader, Board member
40
SEC EDGARColin Broom Md., Board member
41
SEC EDGARCalvin Stiller, Board member
42
SEC EDGARDonald E. Kuhla, Board member
43
SEC EDGARJames G. Groninger, Board member
44
SEC EDGARJohn Robert Evans, Board member
45
SEC EDGARJoseph Klein Iii., Board member
46
SEC EDGARMichael W. Bonney, Board member
47
SEC EDGARPeter G. Tombros, Board member
48
SEC EDGARRachel R. Selisker, Board member
49
SEC EDGARSanto J. Costa, Board member
50
SEC EDGARThomas N. Parks, Board member
51
SEC EDGARHunter Jackson, Board member
52
SEC EDGAREd Stratemeier, General counsel
53
SEC EDGARAndrew D. Rackear, General counsel
54
SEC EDGARVal R. Antczak, General counsel